A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome | C4C

The Phase 1b/2 clinical study intends to investigate the therapeutic potential of a vaccine in development, known as ACI-24.060, for the treatment of AD and AD in individuals with Down Syndrome. The ACI study is divided into two parts, we will focus on study part one, which is investigating ACI-24.060, administered by intramuscular injections versus placebo over a 48-week treatment period and 26-week follow-up period, for patients with prodromal AD. We will not be recruiting for study part two.